Alpha-defensin peptides block gene therapy vectors by preventing them from reaching the cell nucleus | Research

The takeaway

Human alpha-defensins HNP1 and HD5 neutralize AAV gene therapy vectors by blocking viral nuclear entry—HD5 prevents cell binding while both defensins inhibit VP1 domain externalization needed for endosome escape.

Two-step neutralization
Alpha-defensins block AAV gene therapy vectors at both cell binding and nuclear entry steps, revealing a previously unknown barrier to gene delivery

What the researchers found

HD5 prevents AAV2/AAV6 cell binding; both HD5 and HNP1 inhibit VP1 unique domain externalization required for endosome escape and nuclear entry; both defensins prevent AAV from reaching the nucleus. This mechanism parallels how defensins neutralize other non-enveloped viruses.

Why it matters

AAV-based gene therapy is limited by immune responses. Understanding that innate immune peptides (defensins) block AAV at specific intracellular steps provides actionable targets for engineering improved vectors that can evade these defenses and deliver genes more efficiently.

The numbers in context

Both defensins active at low micromolar concentrations against AAV2 and AAV6; block VP1 unique domain externalization.

How the study worked

In vitro mechanistic study using AAV2 and AAV6 vectors with HNP1 and HD5 defensins, assessing cell binding, VP1 domain externalization, intracellular trafficking, and nuclear localization.

Who was studied

N/A (cell culture with human alpha-defensins and AAV vectors)

What this study cannot tell us

In vitro study only. Clinical relevance of defensin-mediated AAV neutralization in patients undergoing gene therapy is not yet established. Only two AAV serotypes and two defensins tested. Defensin concentrations in relevant tissues may vary.

How to read the evidence

Rigorous mechanistic in vitro study with clear molecular mechanisms identified. Strong for basic science but clinical relevance needs validation.

When this study was published

Published in 2025; provides first mechanistic explanation of defensin-AAV interactions.

The bigger picture

Gene therapy efficacy depends on overcoming the body's defenses. While adaptive immunity (antibodies) against AAV is well-studied, this work reveals that innate immune peptides present an additional barrier. Designing AAV vectors resistant to defensin neutralization could significantly improve gene therapy outcomes.

Questions still open

Can AAV capsids be engineered to resist defensin binding while maintaining tissue tropism?
Do defensin levels in patient tissues predict gene therapy efficacy?
Do other antimicrobial peptides also neutralize AAV vectors?

Common questions

What are defensins and how do they affect gene therapy?

Defensins are small antimicrobial peptides produced by immune cells and gut lining. This study found they can neutralize AAV vectors (the most common gene therapy delivery vehicles) by preventing them from entering cell nuclei, potentially reducing gene therapy effectiveness.

Could this be why some gene therapies do not work well?

Possibly. If patients have high defensin levels in tissues targeted by gene therapy, the AAV vectors may be neutralized before delivering their genetic cargo. Understanding this mechanism could help design better vectors or pre-treatment strategies to improve gene therapy outcomes.

Read the original research

Mechanisms of AAV neutralization by human alpha-defensins.

bioRxiv : the preprint server for biology

View on PubMed ↗Publisher’s paper ↗

Citation

Porter, Jessica M; Hulce, Kaitlin R; Oswald, Mackenzi S; Busuttil, Kevin; Emmanuel, Shanan N; Bennett, Antonette; McKenna, Robert; Smith, Jason G. (2025). Mechanisms of AAV neutralization by human alpha-defensins.. bioRxiv : the preprint server for biology. https://doi.org/10.1101/2024.09.25.614754